Stockholders for Cordinus Vascular Robotics on October 25 approved a merger agreement that allows Siemens Healthineers to acquire the robotic catheterization developer.
Cordinus' stockholders also approved the proposal for specified compensation payable to executive officers in connection with the merger.
The transaction is expected to close on October 29. Promptly after the deal closes, Cordinus will be delisted from the NYSE American stock exchange, and its stockholders will receive $4.28 per share without interest.
Siemens plans to integrate Corindus' vascular robotics technology, which aims to support robotic-assisted coronary, peripheral, and neurovascular procedures, into its own portfolio of advanced therapy systems.
